You join a swing dance class, and at first you’re all left feet. But – slowly, eyes glued to the teacher – you pick up a step or two and start to feel the rhythm of the big band beat. A good start.
Following 2019 rejection, FDA adcomm votes against Lexicon’s type 1 diabetes and CKD drug
For the second time in five years, an FDA advisory committee voted against endorsing the benefit-risk profile of Lexicon’s drug sotagliflozin. The Endocrinologic and Metabolic
November 1, 2024